HCPLive

Dr. Kimme Hyrich Discusses Cancer Risk in RA Patients Receiving Anti-TNF Therapies

Kimme L. Hyrich, MD, Arthritis Research UK Epidemiology Unit at University of Manchester, discusses the risk of rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy developing solid cancers.

“When they were first used and available for widespread use, there was a continuing anxiety about whether or not an agent which blocks tumor necrosis factor would actually increase the risk of cancer in patients with rheumatoid arthritis,” said Hyrich.



Most Popular

Recommended Reading

 
$vAR$